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Introduction: varicose veins are tortuous and poorly contractile. Their aetiology remains unclear. Neovascularisation
has been suggested as a possible explanation. Endothelins are mitogenic, promoting proliferation and migration of
endothelial cells via endothelin-B receptors. We hypothesise that endothelial cells and endothelin receptor density and
distribution may play a role in the development of varicosis.
Methods: saphenous vein segments from nine patients with varicose veins were compared to six controls. Slide-mounted
sections were incubated in radioactive labelled endothelin-1 and receptor subtype-selective ligands and binding sites
assessed using autoradiography. Endothelin-1 and endothelial cells were identified by immunohistochemistry and CD31-
positive staining cells counted.
Results: radioactive labelled endothelin-1 and endothelin-B receptor binding was reduced in varicose compared to control
veins (p=0.04). Endothelin-A receptor binding was diffuse, with no difference in density in both groups (p=0.58).
Endothelin-B receptor binding was diffuse with superimposed clusters. Although the density of medial endothelin-B
receptor binding was reduced in the varicose group, more clusters were identified in this group compared to controls
(p=0.005). CD-31 staining identified these clusters as endothelial cells.
Conclusion: the reduced endothelin-1 binding and endothelin-B receptor density may be partially responsible for the
reduced vasocontractility in varicose veins. We speculate that the increase in endothelin-B receptor binding CD31-positive
endothelial cells in varicose veins may potentially stimulate mitogenesis and migration, leading to new vessel formation.
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Introduction a potent smooth muscle mitogen and stimulus for
endothelial cell migration, proliferation and angio-
genesis.11,12 It is produced and released from the endo-Varicose veins are the commonest feature of chronic
thelium in response to several factors includingvenous disease affecting 10–45% of the adult popu-
increased mechanical stress and the presence of throm-lation in Western societies.1,2 The primary cause of
bin, both of which are present in venous hypertensionvenodilatation, poor contractility and recurrence fol-
and varicose veins.13,14 Systemic levels of ET-1 and ET-lowing treatment of varicose veins remains unclear.3
1 receptor affinity have been reported as unchangedThe aetiology, diagnosis and treatment are often ex-
in patients with varicose veins.15 We hypothesise thatplained on the basis of the existence of valvular in-
the density, distribution and function of these en-sufficiency.
dothelin receptors may contribute to the pathogenesisThe primary aetiology of lower limb varicosis may
of varicose veins.however lie in the inherent venous wall weakness
In addition, studies on recurrent varicose veins,as shown by smooth muscle malfunction and
which occur in 20–30% of cases following surgery,abnormalities of the connective tissue collagen and
have suggested a role for neovascularisation in theelastin structure and content.4–7 Smooth muscle main-
aetiology of varicose veins.8,9 Venous tissue blockstenance of venous tone is implemented in part by the
excised from 28 legs undergoing groin re-explorationlocal effect of endogenous vasoconstrictor agents, of
for recurrence showed evidence of neovascularisationwhich endothelin (ET-1) is the most potent.10 This
in 27 groins with the latter as the sole cause of re-endothelium derived 21-amino acid peptide is also
currence in 19 (68%) groins.8 A trial of long saphenous
stripping in 100 patients (133 legs) reported neo-
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cause of recurrence occurring in 52% of limbs.9 The slide-mounted sections in buffer containing radio-
ligand alone (100–150 pmol/L [125I]-ET-1, specificstimuli for these structural and functional defects are
unclear. Although these studies are limited to recurrent activity 2000 Ci/mmol/L, Amersham Pharmacia Bio-
tech, Buckinghamshire, U.K.). ETA binding sites wereveins we speculate that the same process may be
occurring to some degree in primary varicose veins. identified using [125I]-PD 151242 and ETB sites using
[125I]-BQ 3020 (100–150 pmol/L, specific activity of bothThis present study compared the density of ET-1
receptor binding and the distribution of ETA and ETB compounds 2000 Ci/mmol/L, Amersham Pharmacia
Biotech, U.K.).receptor subtypes in varicose veins with those in non-
varicose veins using a combination of in-vitro auto- Non-specific binding for each radioligand was es-
tablished by incubating alternate slides in the presenceradiography and immunohistochemistry.
of 1 mol/L unlabelled ET-1 (Bachem Fine Chemicals,
Basel, Switzerland).
Film autoradiographs were produced by co-expos-
Material and Methods ing radioligand incubated tissue sections with 125I
microscales to Hyperfilm-3H (Amersham Pharmacia
Patients Biotech) in X-ray cassettes for up to 4 days at 4 °C. Films
were then processed according to the manufacturer’s
Venous tissue from nine patients (five males and four instructions. Binding sites were localised at the cellular
females, aged 54±5 years) undergoing primary var- level by dipping incubated sections in molten nuclear
icose vein surgery was obtained. Clinically three emulsion (K2 emulsion, Ilford, Moberley, Cheshire,
patients had venous disease with skin damage (severe, U.K.) and exposing for up to 8 days in lightproof
C4), two had varicose veins with venous oedema boxes at 4 °C. Emulsion was then processed and tissue
(moderate, C3) and four had gross varicosis with stained with Mayer’s haematoxylin and eosin for his-
neither oedema nor skin damage (mild, C2). Although tology.
duplex ultrasound confirmation of long saphenous
incompetence was obtained in the patients, selection
was based on the clinical evidence of overt varicose Quantification of binding
veins. Tissue from six patients (four males and two
females, aged 58±4 years) with no evidence of venous Receptor binding was assessed and quantified by
disease and undergoing coronary artery bypass graft- densitometry using a GS 700 Imager and Densitometer
ing using autologous saphenous vein was obtained as (BioRAD Laboratories, Hercules, California, U.S.A.).
controls. Patients were informed of the procedure and Binding was calculated based on standard curves gen-
consent obtained. erated by 125I microscales. Specific receptor binding
was calculated by subtracting non-specific from total
binding.
Endothelial cells were identified by immuno-Tissue collection
histochemistry using Vector’s avidin-biotin complex
method (ABC Vector Laboratories, Petersborough,The proximal 2 cm of the long saphenous vein was
U.K.). Details of the protocol are as previouslytaken after ligation and division at the saphenofemoral
described.16 Platelet endothelial adhesion molecule-1junction. Utmost care was taken in the handling of the
(PECAM, CD31) antibody for endothelial cellsvein and crushed ends at ligation excised with a sharp
(1:1000 dilution, DAKO Ltd, High Wycombe, Buck-blade. Samples were snap frozen in isopentane/liquid
inghamshire, U.K.) was used to identify the endothelialnitrogen and stored at −80 °C.
cells within the vein sections. ET-1 immunoreactivity
was also identified in a limited number of control and
varicose vein sections using an anti-ET-1 monoclonal
antibody (Peninsula Labs, CA, U.S.A., diluted 1:500).In-vitro autoradiography
Endothelin receptors were identified as previously
described.16 Briefly, slide-mounted vein sections were Cell counts
pre-incubated in 50 mmol/L tris HCl buffer, pH 7.4,
for 15 min at 22 °C in order to reduce endogenous Microscopic images of vein sections were transferred
onto a monitor via a CCD camera attachment on anpeptide levels. Binding was determined by incubating
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Olympus BX50 microscope. ETB clusters and CD31
positive endothelial cells/sites were counted using a
500×500 m grid at ×100-magnification and stand-
ardised to counts per section.
Results were analysed using Microsoft Excel 97 (Mi-
crosoft Inc., Washington DC, U.S.A.) and Graphpad
Prism for Windows statistical packages. Densitometry
was performed on four sections per subject expressed
as mean (confidence intervals) in the text. The final
reading for each patient was the mean total ET-1
binding minus non-specific ET-1 binding for four ad-
jacent vein sections. The results obtained were then
compared using Student’s unpaired t-test. A p-value
<0.05 was considered significant. The CD31 and CD31
ETB counts were per section and compared using
Mann–Whitney U-test.
Results
There was demonstrable ET-1 binding which was as-
sociated with both ETA and ETB receptors in all the
sections studied. Macroscopically, all three radio-
ligands bound to the smooth muscle of the venous
tunica media. Non-specific binding, in the presence of
a saturating concentration of unlabelled ET-1 (1 mol/
L) accounted for 0–15% of total binding (specific bind-
ing therefore 85–100% total binding).
Results of ET-1 binding and ETA and ETB receptor
distribution are depicted in Figure 1. Macroscopic
evaluation of the low-resolution autoradiographs was
suggestive of a lower density of radioligand binding
in the varicose vein group compared to controls.
Results of densitometric evaluation of receptor binding
confirming a reduced binding in varicose veins are
shown in Figure 2. ETA receptor binding was diffusely
distributed across the media while ETB receptors were
distributed diffusely but with obvious clusters of bind-
ing also located within the media. The mean ETA
binding was significantly higher than ETB receptor
binding in both varicose and control groups (p<0.01 Fig. 1. ET-1 receptors on control and varicose veins. Top (upper left):
representative haematoxylin and eosin stained transverse section ofrespectively). There was however, no difference in ETA
long saphenous vein from the control group; (upper right): filmreceptor density between the varicose and control autoradiograph from a section incubated in buffer containing [125I]-
groups (p=0.58; Fig. 2). Mean ETB receptor density ET-1 (mixed ETA and ETB binding); (lower left): autoradiograph
from a section incubated in buffer containing [125I] PD-151242 (ETA);was lower in the varicose vein group compared to the
(lower right): autoradiograph from a section incubated in [125I]control group (p=0.04; Figs 1 and 2). BQ3020 (ETB). Bottom: corresponding autoradiographs of long sa-
There was a significant increase (p=0.005; Mann– phenous vein from the varicose group. Such autoradiographs were
used for densitometric analysis of receptor binding.Whitney) in ETB clusters in varicose veins (30 (5–56))
compared to controls (3 (0–6)). CD31-positive staining
identified the clusters as endothelial cells. There was
also a significant increase (p<0.001; Mann–Whitney) to control veins (167 (117–217)). The ratio of CD31
staining endothelial cells to ETB clusters in the varicosein the mean number of CD31 positive cells/sites in
the varicose veins per section (537 (441–634)) compared vein sections was 0.06 whereas this ratio in the control
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Fig. 2. Low-resolution densitometric analysis comparing ET-1 bind-
ing and ETA/ETB receptor densities in varicose (VV) versus control
(C) saphenous vein sections.
veins was 0.02. These results indicate that the varicose
veins had a higher proportion of ETB binding endo-
thelial cells in the media than control veins.
Immunohistochemistry further demonstrated that
ET-1 was associated with the endothelial cells lining
the lumen of control (not shown) and varicose veins
(Fig. 5), whereas the endothelial cells in the media of
the varicose veins did not exhibit ET-1 immuno-
reactivity. Conversely, medial endothelial cells showed
ETB binding while luminal endothelial cells did not Fig. 3. CD31 immunostaining and ETB binding to medial endo-
(Figs 3 and 4). thelial cells in veins. Top: CD31 immunostaining (brown reaction
product) identifying endothelial cells in control (A) and varicose
vein (B) sections. Note staining of lumenal endothelium of both
vessels and the increase in “migrating” endothelial cells in B.
Bottom: ETB binding to endothelial cells of varicose vein. There
Discussion is a high number of endothelial cells (CD31 staining) in the
media (C), but only a proportion of these exhibit ETB receptors
(dark grain accumulations) on a haematoxylin and eosin stainedVaricose veins are distended tortuous and poorly con- adjacent section (D). Scale bar=50 m for A and B; Scale bar=
tractile veins of uncertain aetiology. They have a 25 m for C and D.
familial tendency and are prone to recurrence even
after meticulous surgery.17–20 Varicose veins exhibit
diminished contractile responses to potent vasoactive vasoactive agents such as noradrenaline, angiotensin
and ET-1. ET-1 is a 21 amino acid peptide with a shortagents – norepinephrine, angiotensin and endothelin.21
Of these vasoactive agents, endothelin is the most plasma half-life.22 Since ET-1 was first isolated from
porcine endothelial cells in 1988,11 it has been im-potent. This discussion is based on the two main
findings in our study. Firstly, the diminished medial plicated in a host of cardiovascular diseases and path-
ologies involving altered smooth muscle contractilityendothelin binding and receptor density in varicose
veins, which may in part account for the poor con- in tubular organs.12,16,22 Its action is likely to be at
local tissue level rather than systemic. ET-1 inducedtractile response in these vessels. Secondly, the marked
increase in ETB receptor binding to endothelial cells vasocontractility is mediated via both ETA and ETB
receptor subtypes.23 The presence of both receptorin the varicose vein wall, which we speculate, may
mediate neovascularisation as a potential cause of subtypes has been demonstrated in human long sa-
phenous vein.24 Contractions to ET-1 are diminishedvaricose veins.
The maintenance of venous tone is dependent on in varicose veins compared to control veins.21 Further
studies have shown similar plasma levels of ET-1 andthe action of the sympathetic nervous system and
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Fig. 4. ETB receptor distribution on sections of varicose vein. (a); Section used for the identification of endothelial cells (positive CD31
staining shown by brown reaction product). (b); High resolution autoradiograph of ETB receptors ([125I]-BQ3020 binding) on an adjacent
section of varicose vein (haematoxylin and eosin stained, binding shown as dark grain accumulations). (c); Dark-field illumination of (b),
where binding sites shown as white grains on a dark background. These clusters of ETB binding sites are associated with a proportion of
endothelial cells within the media of the varicose vein but not with the lumenal endothelium. Scale bar=50 m.
to leg veins, Blochl-Daum et al. have reported defective
contractile responses to vasoactive agents in the hand
veins of patients with varicose veins compared to
controls without varicose veins.25 Decreased binding
and receptor availability may partly account for the
impaired tone and contractility in varicose veins.
Whether this is the primary insult or the result of
disease progression is unclear at this stage.
Varicose veins have been shown to have a higher
blood flow rate and increased blood oxygenation than
non-varicose veins.26,27 These observations have been
associated with the often quoted but rather debatable
arteriovenous fistulae theory in the aetiology of var-
icose veins.28–30 Experimental arteriovenous fistulae in
canine veins have been shown to be associated withFig. 5. Endothelin-1 immunoreactivity on varicose vein. (a);
Positive ET-1 immunoreactivity (brown stain) associated with a modulation of contractility. While the increased shear
lumenal endothelium, with some staining also of medial smooth associated with increased flow upregulated ET re-muscle. (b); CD31 immunostaining of an adjacent section iden-
ceptors in arteries,31 the reverse was the case in A-Vtifying the lumenal endothelium and “migrating” cells within
the media. ET-1 immunostaining is restricted to the lumenal fistulated canine veins with receptor down regulation
endothelium. Scale bar=50 m.
and a reduced maximal contractility response to ET-
1.32 Although these studies are yet to be confirmed in
humans, we speculate that the chronic exposure of
varicose veins to high flow, stress or oxygenation maysimilar ET receptor affinities in varicose and non-
be contributory to the desensitisation or reduction invaricose veins.15 Our study demonstrated a reduced
ET receptors as shown by our study.density of ET-1 binding and ETB receptor subtypes
In addition to its effect on vascular tone, ET-1 hasin varicose veins and suggests a fundamental local
been shown to have mitogenic and angiogenic prop-reduction in receptor availability (Fig. 2). These find-
erties.33–35 ET-1 is produced by endothelial cells. Growthings are in keeping with similar studies on pulverised
and migration of endothelial cells control the vascularveins.15 Whether the reduced contractility is due
remodelling that is necessary for healing and is as-to desensitisation, internalisation, degenerative or
sociated with various vascular diseases. Morbidelli etgenetically determined lowering in absolute receptor
numbers is unclear. Although our study was limited al. have shown that ET-1 stimulates endothelial cell
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growth and mobilisation, thus contributing to neo- of the clusters of ETB receptors on endothelial cells in
varicose veins may enhance neovascularisation as avascularisation.36 This autocrine effect is mediated via
potential cause of primary and recurrent varicoseETB receptors. Our study showed a reduction in ETB
veins.receptor binding to the tunica media in the varicose
vein group, whereas there was discrete clustering of
ETB receptors in this region (Figs 3 and 4). Initially, it
was thought that these clusters might represent bind-
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